- 1 Glaucoma medication adherence and associated factors
- 2 among adult glaucoma patients in Ethiopia: A systematic
- 3 review and meta-analysis
- 4 Kibruyisfaw Weldeab Abore<sup>1\*</sup>, Estifanos Bekele Fole<sup>2</sup>, Mahlet Tesfaye Abebe<sup>2</sup>, Natnael Fikadu
- 5 Tekle<sup>3</sup>, Robel Bayou Tilahun<sup>3</sup>, Fraol Daba Chinkey<sup>4</sup>, Michael Teklehaimanot Abera<sup>5</sup>
- <sup>1</sup>Department of Pediatrics, Yirgalem Hospital Medical College, Yirgalem, Sidama, Ethiopia
- 8 <sup>2</sup>Department of Medicine, Yirgalem Hospital Medical College, Yirgalem, Sidama, Ethiopia
- 9 <sup>3</sup>Long term care department, Burjeel Medical City, Abu Dhabi, United Arab Emirates
- <sup>4</sup>Bin Haider Healthcare Center, Dubai, United Arab Emirates
- <sup>5</sup> Department of radiology, College of Health Sciences, Addis Ababa University, Addis Ababa,
- 12 Ethiopia

14

17

6

- \*Corresponding author:
- 16 Kibruyisfaw Weldeab Abore (<u>Kibruyisfaww@gmail.com</u>)

## **Abstract**

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

**Background:** Glaucoma medications are one important pillar of glaucoma management to control intraocular pressure. If left uncontrolled, intraocular pressure causes progressive visual loss and blindness. Thus, adherence to glaucoma medication is vital to prevent optic nerve damage and its consequences. This study was conducted to systematically summarize the magnitude of glaucoma medication adherence and the associated factors among adults with glaucoma in Ethiopia. **Methods:** Database Searches to identify research articles was conducted on PubMed, EMBASE, Cochrane, AJOL, SCOPUS, and Google scholar without restriction on the date of publication. Data extraction was done using a data extraction Excel sheet. Analysis was performed using STATA version 16. Heterogeneity was assessed using I<sup>2</sup> statistics. Pooled prevalence and pooled odds ratio with a 95% confidence interval using a random effect model were computed. **Result:** We included 6 studies with a total of 2101 participants for the meta-analysis. The magnitude of adherence to glaucoma medication was found to be 49.46% (95% CI [41.27-57.66]). Urban residence (OR=1.89, 95% CI; 1.29-2.49), normal visual acuity (OR=2.82, 95% CI; 0.85-4.80, P=0.01), and payment means for medication (OR=0.22, 95% CI; 0.09-0.34) were found to be statistically significant predictors of adherence. **Conclusion:** The magnitude of glaucoma medication adherence is lower than expected. Place of residence, visual acuity, and payment means had statistically significant associations with

- 40 glaucoma medication adherence. Tailored health education on medication adherence and
- 41 subsidization of glaucoma medication is recommended.

## Introduction

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

Glaucoma is a preventable cause of blindness which primarily is the disease of the optic nerve [1]. Globally, it is estimated to affect around 80 million individuals and cause blindness in 3.6 million individuals [2, 3]. Previous studies have shown that there are various risk factors to develop glaucoma. High intraocular pressure is a modifiable risk factor which is a target of treatment among glaucoma patients [4]. Currently available treatment modalities that include medical, surgical, and laser therapy are all primarily designed to lower the IOP [5]. Successful medical treatment of patients with glaucoma is contingent upon the adherence of the patients to the prescribed medication [6, 7]. Adherence is defined as the degree to which the patient takes the prescribed medication according to the prescription given by a health professional [6]. Adherence to glaucoma medication has been shown to decrease the progressive visual field loss and subsequent loss of vision among glaucoma patients [8, 9]. Although it is highly unreliable and prone to bias, self-reporting is the most commonly used method of assessing adherence [10, 11]. Previous studies done in different parts of the world have reported a highly variable level of non-adherence ranging from 5% to 80% [12]. Furthermore, Studies done in Ethiopia have also reported level of adherence ranging from 32.5% [13] to 61.4% [14]. Some of the factors associated with adherence to glaucoma medication include sociodemographic factors, poor understanding of the disease and its course, baseline line clinical condition, and medication related factors such as dosing, side effects, and costs of medication [15-19].

- The magnitude of adherence and the factors affecting it reported in studies conducted in Ethiopia
- varies greatly. Therefore, this study aims to synthesize the pooled overall magnitude of glaucoma
- medication adherence and its associated factors among adult glaucoma patients in Ethiopia.

## Methods and materials

## Study design and Study setting

- A systematic review and meta-analysis were done to assess the magnitude of glaucoma
- 68 medication adherence and associated factors among adult glaucoma patients in Ethiopia. The
- 69 protocol for the systematic review was registered on PROSPERO (Registration number:
- 70 CRD42023449004).

65

66

71

73

74

75

76

77

78

79

80

81

82

83

84

## Search strategy

A comprehensive and systematic search of articles from PubMed, EMBASE, Cochrane, AJOL,

SCOPUS, and Google scholar databases was made using the search terms (("anti-glaucoma" OR

"glaucoma medication" OR "glaucoma drug" OR "topical anti-glaucoma") AND (adherence OR

compliance)) AND ("Ethiopia"). The full PubMed search was ("anti-glaucoma"[All Fields] OR

"glaucoma medication"[All Fields] OR "glaucoma drug"[All Fields] OR "topical anti-

glaucoma"[All Fields]) AND ("adherance"[All Fields] OR "adhere"[All Fields] OR

"adhered"[All Fields] OR "adherence"[All Fields] OR "adherences"[All Fields] OR

"adherent" [All Fields] OR "adherents" [All Fields] OR "adherer" [All Fields] OR "adherers" [All

Fields] OR "adheres" [All Fields] OR "adhering" [All Fields] OR ("compliances" [All Fields] OR

"patient compliance" [MeSH Terms] OR ("patient" [All Fields] AND "compliance" [All Fields])

OR "patient compliance" [All Fields] OR "compliance" [All Fields] OR "compliance" [MeSH

Terms])) AND "Ethiopia"[All Fields]. The search was made up to September 2023 with

restriction to only articles published in English. The Preferred Reporting Items for Systematic

reviews and Meta-Analyses (PRISMA) guideline [20] was used to document and report the steps of study selection.

## Eligibility criteria

85

86

87

88

92

95

96

97

98

99

100

101

102

103

#### **Inclusion criteria**

This review included studies (cross-sectional, cohort, and case-control studies) that evaluated glaucoma medication adherence and/or its associated factors among adults in Ethiopia with no restriction on the year of publication of the study.

#### **Exclusion criteria**

93 Studies conducted outside of Ethiopia and studies which are not published in English language 94 were excluded from the study.

## Quality appraisal

Quality assessment of the included studies was done using the Newcastle-Ottawa scale (NOS) by three reviewers independently [21]. It assesses bias in 3 domains namely selection, comparability, and outcome domains. Those with a grade of less than 7 were assessed as poor and those with greater than or equal to 7 were assessed as having good quality. Disagreement in scoring between reviewers was settled by discussion with the help of a fourth reviewer.

### **Data extraction**

Two reviewers searched databases and applied the eligibility criteria independently to select studies. Covidence was used to manage articles. Examination of the selected studies against the

eligibility criteria was done by two reviewers. Data extraction from selected studies was done by two reviewers independently and examination of the extracted data was done by a third reviewer. Differences between the reviewers were resolved through discussion and when agreement was not reached a third reviewer was involved to mediate. A pre-prepared EXCEL data extraction sheet was utilized to extract data from included studies which included the name of the primary author, region of the country, year of publication, study design, sample size, magnitude of adherence to anti-glaucoma medication, and risk factors with the corresponding measure of effect.

## Data analysis

Data was exported from Excel to STATA v.16 for analysis. Pooled magnitude of adherence and pooled odds ratio with a 95% confidence interval was computed using random effect model with the DerSimonian-Laird method and presented using a forest plot. To calculate the pooled odds ratio, we included variables which were reported as a statistically significant variable in at least two studies. Heterogeneity was assessed using I<sup>2</sup> statistics and meta-regression was done to identify potential sources of heterogeneity. Furthermore, subgroup analysis was conducted based on the method of adherence ascertainment used by the studies. Publication bias was assessed using funnel plot and Eggers test.

## Result

#### Search results

After searching various databases, we were able to retrieve a total of 172 articles. We removed 20 articles due to duplication and 144 articles were excluded after reviewing the title and abstract. After a full article review, 6 studies reporting wrong outcomes were excluded. In addition, 1 study with a full article not retrievable and 1 study done in a similar hospital as the study included in the final review were excluded from the review. A total of 6 Articles were considered for full article review against the eligibility criteria and included in the final review. (Fig 1)

- Fig 1. PRISMA study selection flow for systematic review and meta-analysis of Glaucoma
- medication adherence and associated factors among adults in Ethiopia.

## **Study characteristics**

All of the included primary studies used a cross-sectional study design. Of the studies, 1 was done in Sidama region [22], 1 in Addis Ababa [23], 1 study done in Oromia region [13], and 3 studies were done in Amhara region [14, 24, 25]. The studies were published between 2015 and 2023 and included a sample size ranging from 200 [13] to 410 [22]individuals. The total number of participants included in the review was 2101. Regarding the method of ascertainment of adherence, all of the included studies used self-reporting by the patient to declare adherence. Of the studies, 4 of them used a tool designed by the authors for the study [13, 14, 22, 24] while 2 studies used the Morisky medication adherence scale-8 [23, 25]. All included studies had good quality based on NOS score.

## Table 1. Study characteristics of included studies on Glaucoma medication adherence and

#### associated factors among adult glaucoma patients in Ethiopia

Authors	Year of publication	Region	Study design	SS	NOS score	Adherence (95% CI)
Melaku M. Et al[22]	2023	Sidama	Cross- sectional	410	7	53.9% (48.8-58.5)
Birhanie et al[25]	2022	Amhara	Cross- sectional	382	8	49.5% (44.4-54.5)
Assem et al[24]	2020	Amhara	Cross- sectional	390	7	56.2% (51-62)
Anbesse et al[14]	2018	Amhara	Cross- sectional	360	7	61.4% (56.1-66.7)
Mehari T. et al[23]	2016	Addis Ababa	Cross- sectional	359	7	42.6% (37.38-47.83)
Tamrat et al[13]	2015	Oromia	Cross- sectional	200	7	32.5%(25.8-39.2)

SS; sample size, NOS; Newcastle Ottawa score

## Magnitude of glaucoma medication adherence

We used 6 studies with a total of 2101 participants to estimate the pooled prevalence of magnitude of glaucoma medication adherence. There was a statistically significant high heterogeneity among studies based on I<sup>2</sup> ( I<sup>2</sup>=92.82%) and a random effect model with the DerSimonian-Laird method was used to determine the pooled magnitude. The magnitude of adherence among adult glaucoma patients was found to be 49.46% (95% CI; 41.27-57.66) (**Fig** 2). To explore potential sources of heterogeneity, meta-regression was done using sample size and publication year as covariates and both had no effect on the heterogeneity (**Table 2**). Subgroup analysis was done based on the method used to classify adherence. The pooled magnitude of adherence for studies that used a tool prepared by the author was found to be 51.13% (95%

157 CI; 38.83-63.43) and for studies that used the MMAS-8 it was found to be 46.08% (95% CI;

158 39.32-52.85) (**Fig 3**).

159

160

161

162

163

164

165

166

168

170

Fig 2. Forrest plot for the pooled magnitude of adherence to glaucoma medication among

adult glaucoma patients in Ethiopia

#### Table 2. Meta-regression analysis of factors affecting between-study heterogeneity.

Source	Coefficient	Std. error	p-value
Sample size	.109635	0.076137	0.15
Publication year	-0.04151	1.763183	0.981

#### Fig 3. Forrest plot for the pooled magnitude of adherence to glaucoma medication among

adult glaucoma patients based on the method of adherence classification used

#### **Publication bias**

- Publication bias was assessed using a funnel plot and Eggers test (p=0.0596) which revealed
- there was no publication bias (Fig 4).
  - Fig 4. Funnel plot assessing publication bias of the magnitude of glaucoma medication
- adherence among adult glaucoma patients in Ethiopia

## Factors associated with glaucoma medication adherence

- We included variables that were significantly associated with adherence in at least two or more
- of the studies.

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

Association between place of residence and glaucoma medication adherence We used three studies with 1160 participants [14, 22, 24] to assess the association between place of residence and adherence. The odds of adherence to glaucoma medication was found to be 1.89 times higher among urban residents than rural residents (OR=1.89, 95% CI; 1.29-2.49). (Fig 5) Fig 5. Association between place of residence and glaucoma medication adherence Association between visual acuity and glaucoma medication adherence We used three studies with 1160 participants [14, 22, 24] to assess the association between visual acuity and adherence. The odds of adherence to glaucoma medication was found to be 2.82 times higher among patients with normal visual acuity than those with affected visual acuity (OR=2.82, 95% CI; 0.85-4.80, P=0.01). (**Fig 6**) Fig 6. Association between visual acuity and glaucoma medication adherence Association between means of payment and glaucoma medication adherence We used two studies to examine the association between means of payment for medication and adherence with a total of 719 study participants [14, 23]. It was found that those who pay for the glaucoma medication themselves had 78% lower odds of adherence to glaucoma medication than those who are sponsored (OR=0.22, 95%CI; 0.09-0.34). (Fig 7) Fig 7. Association between means of payment and glaucoma medication adherence

## **Discussion**

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

A systematic review and meta-analysis were done to determine the magnitude of glaucoma medication adherence and factors associated with it among adult glaucoma patients. It was found that less than half of glaucoma patients (49.46%) adhered to the prescribed medication. This finding is comparable with a study done in Ghana (48.5%) [26], Egypt (46.4%) [27], and higher than reported in Togo (10%) [28] and Iran (34.6%) [17]. However, it is lower than studies conducted in Benin (53%) [29], Israel (71%)[30], Saudi Arabia (72.6%) [31], and Korea (72.6%)[32]. This variation could be due to differences in socioeconomic profiles, differences in the health systems and health insurance coverage of the countries, differences in definition and method of ascertainment of adherence as well as variation in sample size. In this study, it was found that those residing in urban areas had 1.89 times higher odds of adherence than those residing in rural areas. A study done in Iran in 2015 had also reported a statistically significant association between place of residence and medication adherence [17]. This could be due to the differences in access to health care and health related information and differences in access to health services like pharmacies for medication refill. Furthermore, those with normal vision had 2.82 times higher odds of adherence to glaucoma medication compared to those with affected vision. This could be related to the dissatisfaction with the lack of change in the disease among those with affected visual acuity [17, 30]. Additionally, those who have impaired visual acuity are highly likely to be dependent for their day to day activities including application of the medication, purchasing medication, and going to health facilities for follow-up. A study done in Israel had also shown that there is a

statistically significant association between functional dependence and glaucoma medication adherence (p=0.005)[30].

Those who paid for the medication by themselves had 78% lower odds of adherence than those who were sponsored for their medication. This finding is in comparative agreement with studies done in Nigeria [33], Ghana [34], and Romania[35] that reported the cost of the medication as a significant barrier to glaucoma medication adherence. The finding could be attributed to the long course of treatment, the high cost of glaucoma medication coupled with the poor socioeconomic status of Ethiopian community. This effect could be more pronounced among those who are on multiple glaucoma medications [17, 27] and those with comorbidities taking other medications.

## Limitation

This study is affected by recall bias and desirability bias inherent to the primary studies that used a self-reporting method of adherence ascertainment. This could potentially lead to overestimation of adherence to medication. Moreover, only 4 out of the 12 regions of Ethiopia are represented in the study which makes the finding less generalizable to Ethiopia.

## Conclusion

The magnitude of adherence to glaucoma medication adherence is low among adult glaucoma patients in Ethiopia. Area of residence, visual acuity, and means of payment had a statistically significant association with glaucoma medication adherence. Tailored health education to those coming from rural areas and those with affected visual acuity regarding glaucoma and drug adherence is recommended. Additionally, availing glaucoma medication at a subsidized price to those who cannot afford to buy medication and expanding community health insurance is

- recommended. We also recommend further studies using objective methods of assessment of
- adherence to be done.

237

238

239

240

## References

- 241 1. AAO. <a href="https://eyewiki.aao.org/Primary\_Open-Angle\_Glaucoma">https://eyewiki.aao.org/Primary\_Open-Angle\_Glaucoma</a> 2023 [cited 2023 26-09].
- 242 Available from: <a href="https://eyewiki.aao.org/Primary\_Open-Angle\_Glaucoma">https://eyewiki.aao.org/Primary\_Open-Angle\_Glaucoma</a>.
- 243 2. Steinmetz JD, Bourne RR, Briant PS, Flaxman SR, Taylor HR, Jonas JB, et al. Causes of blindness
- and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in
- relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The
- 246 Lancet Global Health. 2021;9(2):e144-e60.
- 247 3. Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a
- meta-analysis and systematic review. Scientific Reports. 2021;11(1):13762.
- 249 4. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of
- 250 intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol.
- 251 2000;130(4):429-40.
- 252 5. Conlon R, Saheb H, Ahmed IIK. Glaucoma treatment trends: a review. Canadian Journal of
- 253 Ophthalmology. 2017;52(1):114-24.
- 254 6. Robin AL, Muir KW. Medication adherence in patients with ocular hypertension or glaucoma.
- 255 Expert Review of Ophthalmology. 2019;14(4-5):199-210.
- 256 7. Sleath B, Blalock S, Covert D, Stone JL, Skinner AC, Muir K, et al. The Relationship between
- 257 Glaucoma Medication Adherence, Eye Drop Technique, and Visual Field Defect Severity. Ophthalmology.
- 258 2011;118(12):2398-402.
- 259 8. Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The association
- 260 between medication adherence and visual field progression in the Collaborative Initial Glaucoma
- 261 Treatment Study. Ophthalmology. 2020;127(4):477-83.
- 262 9. Shu YH, Wu J, Luong T, Mattox C, Fang EN, Lee BL, et al. Topical Medication Adherence and
- 263 Visual Field Progression in Open-angle Glaucoma: Analysis of a Large US Health Care System. J
- 264 Glaucoma. 2021;30(12):1047-55.
- 265 10. Schwartz GF, Quigley HA. Adherence and Persistence with Glaucoma Therapy. Survey of
- 266 Ophthalmology. 2008;53(6, Supplement):S57-S68.

- 267 11. Sayner R, Carpenter DM, Blalock SJ, Robin AL, Muir KW, Hartnett ME, et al. Accuracy of Patient-
- 268 reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic
- 269 Monitors. Clinical Therapeutics. 2015;37(9):1975-85.
- 270 12. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive
- treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology.
- 272 2005;112(6):953-61. e7.
- 273 13. Tamrat L, Gessesse GW, Gelaw Y. Adherence to topical glaucoma medications in Ethiopian
- patients. Middle East Afr J Ophthalmol. 2015;22(1):59-63.
- 275 14. Anbesse DH, Yibekal BT, Assefa NL. Adherence to topical glaucoma medications and associated
- factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia. Eur J Ophthalmol.
- 277 2019;29(2):189-95.
- 278 15. Dreer LE, Girkin C, Mansberger SL. Determinants of medication adherence to topical glaucoma
- 279 therapy. J Glaucoma. 2012;21(4):234-40.
- 280 16. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a
- 281 systematic classification. Journal of glaucoma. 2003;12(5):393-8.
- 282 17. Movahedinejad T, Adib-Hajbaghery M. Adherence to treatment in patients with open-angle
- glaucoma and its related factors. Electronic physician. 2016;8(9):2954.
- 284 18. Salman M, Andrews C, Heisler M, Darnley-Fisch D, Newman-Casey PA. Psychosocial Predictors of
- 285 Glaucoma Medication Adherence Among the Support, Educate, Empower (SEE) Personalized Glaucoma
- 286 Coaching Pilot Study Participants. American Journal of Ophthalmology. 2020;216:207-18.
- 287 19. Moore SG, Richter G, Modjtahedi BS. Factors Affecting Glaucoma Medication Adherence and
- 288 Interventions to Improve Adherence: A Narrative Review. Ophthalmology and Therapy. 2023.
- 289 20. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny
- app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital
- transparency and Open Synthesis. Campbell Systematic Reviews. 2022;18(2):e1230.
- 292 21. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al. Panethnic
- 293 differences in blood pressure in Europe: a systematic review and meta-analysis. PloS one.
- 294 2016;11(1):e0147601.
- 295 22. Melaku MW, Yibekal BT, Demilew KZ. Adherence to topical anti-glaucoma medications in
- 296 Sidama regional state, Southern Ethiopia. Plos one. 2023;18(4):e0284200.
- 297 23. Mehari T, Giorgis AT, Shibeshi W. Level of adherence to ocular hypotensive agents and its
- 298 determinant factors among glaucoma patients in Menelik II Referral Hospital, Ethiopia. BMC
- 299 Ophthalmol. 2016;16:131.
- 300 24. Assem AS, Fekadu SA, Yigzaw AA, Nigussie ZM, Achamyeleh AA. Level of Glaucoma Drug
- 301 Adherence and Its Associated Factors Among Adult Glaucoma Patients Attending Felege Hiwot
- 302 Specialized Hospital, Bahir Dar City, Northwest Ethiopia. Clin Optom (Auckl). 2020;12:189-97.
- 303 25. Birhanie SA, Getie GA, Tesfa M, Mulugeta H, Gedfew M, Mekete YS, et al. Treatment adherence
- and associated factors among glaucoma patients attending Ophthalmic units of referral hospitals in
- North West Ethiopia, 2019. Frontiers in Ophthalmology. 2022;2:985893.
- 306 26. Kyei S, Kwao E, Mashige PK, Listowell Abu S, Racette L. Adherence to Ocular Hypotensive
- 307 Medication in Patients With Primary Open Angle Glaucoma in Ghana. Journal of Glaucoma.
- 308 2023;32(9):777-82.
- 309 27. Abu Hussein NB, Eissa IM, Abdel-Kader AA. Analysis of factors affecting patients' compliance to
- 310 topical antiglaucoma medications in Egypt as a developing country model. Journal of ophthalmology.
- 311 2015;2015.
- 312 28. Santos MAK, Ayena DK, Kuaovi KR, Vonor K, Djagnikpo A, Balo KP. [Compliance with medical
- treatment in primary open-angle glaucoma in Lomé]. J Fr Ophtalmol. 2016;39(5):459-66.

- 314 29. Tchabi S, Abouki C, Sounouvou I, Yèhouessi L, Doutetien C, Bassabi S. Survey of medical
- treatment in primary open-angle glaucoma. J Fr Ophtalmol. 2011;34(9):624-8.
- 316 30. Cohen Castel O, Keinan-Boker L, Geyer O, Milman U, Karkabi K. Factors associated with
- adherence to glaucoma pharmacotherapy in the primary care setting. Family practice. 2014;31(4):453-
- 318 61.
- 319 31. Shadid A, Alrashed W, Shihah AB, Alhomoud A, Alghamdi M, Alturki A, et al. Adherence to
- 320 medical treatment and its determinants among adult saudi glaucoma patients in riyadh city. Cureus.
- 321 2020;12(2).
- 322 32. Kim CY, Park KH, Ahn J, Ahn M-D, Cha SC, Kim HS, et al. Treatment patterns and medication
- 323 adherence of patients with glaucoma in South Korea. British Journal of Ophthalmology.
- 324 2017;101(6):801-7.
- 325 33. Abdull MM, Chandler C, Gilbert C. Glaucoma, "the silent thief of sight": patients' perspectives
- and health seeking behaviour in Bauchi, northern Nigeria. BMC Ophthalmology. 2016;16(1):44.
- 327 34. Ocansey S, Kyei S, Diafo A, Darfor KN, Boadi-Kusi SB, Aglobitse PB. Cost of the medical
- 328 management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a
- 329 retrospective cross-sectional study from three referral facilities. BMC health services research.
- 330 2016;16(1):1-8.

- 331 35. Zaharia A-C, Dumitrescu O-M, Radu M, Rogoz R-E. Adherence to Therapy in Glaucoma
- 332 Treatment—A Review. Journal of Personalized Medicine. 2022;12(4):514.

## 334 Supporting information

- 335 S1. PRISMA 2020 checklist
- 336 **S2. Data set**

Reports of new included studies

(n = 0)

New studies included in review

(n = 6)

medRxiv preprint doi: https://doi.org/10.1101/2023.10.05.232

review) is the author/funder, who has
It is made available under a CC-By

Reports assessed for eligibility

(n =

granted medRxiv a licen 4.0 International license

sion posted October 5, 2023. The copyright holder for this preprint

Reports sought for retrieval

(n =

24)



Identification of new studies via databases and registers

Records marked as ineligible by automation Duplicate records (n = 20) tools (n = 0)

Records removed before screening:

Records removed for other reasons (n = 0)

(n = 128)

Records excluded

Records screened (n = 152)

Reports not retrieved

(n = 1)

Study done outside Ethiopia (n = 10) Reports excluded:


Wrong outcome (n = 6)

similar study done in the same hospital (n = 1)


PRISMA flow diagram

Study		Effect Size with 95% CI	Weight (%)
Author prepared			
Melaku MW. Et al		53.90 [49.05, 58.75]	16.93
Assem et al		56.20 [ 50.70, 61.70]	16.65
Anbesse et al		61.40 [ 56.10, 66.70]	16.74
Tamrat et al		32.50 [25.80, 39.20]	16.06
Heterogeneity: $\tau^2 = 149.34$ , $I^2 = 94.96\%$ , $H^2 = 19.83$		51.13 [ 38.83, 63.43]	
Test of $\theta_i = \theta_j$ : Q(3) = 46.99, p = 0.00			
MMAS-8			
Birhanie et al		49.50 [ 44.45, 54.55]	16.85
Mehari et al		42.60 [ 37.38, 47.83]	16.77
Heterogeneity: $\tau^2 = 16.93$ , $I^2 = 71.13\%$ , $H^2 = 3.46$		46.08 [ 39.32, 52.85]	
Test of $\theta_i = \theta_j$ : Q(1) = 3.46, p = 0.06			
Overall Heterogeneity: $\tau^2 = 97.10$ , $I^2 = 92.82\%$ , $H^2 = 13.92$ Test of $\theta_i = \theta_j$ : Q(5) = 58.88, p = 0.00		49.46 [41.27, 57.66]	
Test of group differences: $Q_b(1) = 0.50$ , $p = 0.48$	30 40 50 60	70	

## Figure




Figure




Effect Size

Weight



Effect Size

Weight




Effect Size

with 95% CI

Weight

# Figure



Weight

Effect Size

Figure